Sarepta Rises as Drug Betters Conditions of Rare Muscle DiseaseBy
Patients on eteplirsen able to walk farther than benchmark
Data aids Sarepta in battle with BioMarin to treat DMD
Sarepta Therapeutics Inc. rose the most in more than four months after its mid-stage trial showed improved walking capability and increased muscle protein for patients with a rare and deadly muscle-wasting disease.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.